iBio, Inc. Common Stock (IBIO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $49.79M
Last updated: Nov 17, 2026 at 4:10 PM ET
iBio, Inc. Common Stock (IBIO) Stock Chart
iBio, Inc. Common Stock (IBIO) has a latest price of $0.75 on Nov 17, 2026, 80.4% below its 52-week high of $3.82. Its price fell 35.5% over the past 12 months. The month-end price fell 100.0% over the 10 years through Oct 2026, a compound annual decline of 55.6%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $2,600.00 in Oct 2016 and its lowest $0.68 in Jul 2025, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart IBIO with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for IBIO.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 49.8%, and over 6 months it fell 50.1%. The month-end price fell 85.4% over the 3 years through Oct 2026, a compound annual decline of 47.3%.
| Period | Change |
|---|---|
| 1 month | -1.6% |
| 3 months | -49.8% |
| 6 months | -50.1% |
| 12 months | -35.5% |
| 12 months, with dividends | -35.5% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -85.4% | -47.3% |
| 5 years | -99.8% | -71.2% |
| 10 years | -100.0% | -55.6% |
Price by Year
Its best calendar year was 2020, when the price rose 320.0%, and its weakest was 2022, when it fell 96.8%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $0.77 | -60.2% |
| 2025 | $1.93 | -21.2% |
| 2024 | $2.45 | +78.8% |
| 2023 | $1.37 | -84.6% |
| 2022 | $8.89 | -96.8% |
| 2021 | $274.50 | -47.7% |
| 2020 | $525.00 | +320.0% |
| 2019 | $125.00 | -66.8% |
| 2018 | $376.70 | -58.1% |
| 2017 | $900.00 | -54.4% |
Trading Range
The price is 21.7% below its 50-day average of $0.96 and 53.4% below its 200-day average of $1.61.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $0.75 | |
| 52-week high | $3.82 | -80.4% |
| 52-week low | $0.68 | +10.8% |
| 50-day average | $0.96 | -21.7% |
| 200-day average | $1.61 | -53.4% |
Price Risk
Over 3 years, its largest fall from a peak was 91.1%.
| Measure | Value |
|---|---|
| 1-year beta | 2.25 |
| Largest fall, 1 year | -77.0% |
| Largest fall, 3 years | -91.1% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About IBIO
What is IBIO's 1-year price change?
iBio, Inc. Common Stock's price fell 35.5% over the past 12 months. With dividends included, the 12-month total return was -35.5%.
What is IBIO's 5-year price change?
iBio, Inc. Common Stock's month-end price fell 99.8% over the 5 years through Oct 2026, a compound annual decline of 71.2%. These figures leave out dividends.
What is IBIO's 52-week high and low?
iBio, Inc. Common Stock's 52-week high is $3.82 and its 52-week low is $0.68. Its latest price of $0.75 on Nov 17, 2026 is 80.4% below the high.
What is IBIO's beta?
iBio, Inc. Common Stock's 1-year beta against the S&P 500 is 2.25, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 77.0%.
Is the IBIO chart free?
Yes. Advanced Charting for IBIO is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
IBIO pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors